相关实验视频
Updated: Jun 10, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
793
抗血小板治疗对COVID-19的影响
Juntendo Iji zasshi = Juntendo medical journal
|October 21, 2024
概括
SARS-CoV-2 影响血小板,增加COVID-19中血栓形成的风险. 如果在中度病例中早期开始,抗血小板治疗可能会成功,这证明了未来临床试验的必要性.
科学领域:
- 血液学 血液学 血液学
- 病毒学 病毒学
- 心血管医学 心血管医学
背景情况:
- SARS-CoV-2 感染显著影响血小板功能.
- 活化血小板有助于COVID-19患者观察到的前血栓状况.
- 目前的国际指导方针不建议对COVID-19进行抗血小板治疗.
研究的目的:
- 分析血小板在COVID-19相关血栓形成中的作用.
- 研究抗血小板治疗在COVID-19中的潜在疗效.
- 为了确定COVID-19中抗血栓治疗的最佳条件.
主要方法:
- 对COVID-19和血栓形成现有临床研究的审查.
- 在SARS-CoV-2感染中分析血小板激活途径.
- 对抗凝血剂治疗的临床试验结果进行比较.
主要成果:
- 血小板激活由SARS-CoV-2导致前血栓性物质释放和凝血激活.
- 目前针对COVID-19的抗血小板治疗的临床试验已经产生了不确定的结果.
- 抗凝固药治疗研究表明,在中度严重病例中,早期启动治疗对于成功至关重要.
结论:
- 开始的时间和目标患者的严重程度是COVID-19抗血小板治疗成功的关键因素.
- 未来的临床试验应在精心挑选的COVID-19患者群体中探索抗血小板干预措施,重点关注中度疾病的早期治疗.
- 优化抗血栓策略,包括抗血小板剂,需要在特定的COVID-19背景下进一步调查.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
478
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
478
Coronary Artery Disease V: Surgical Management
3
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
3
Anticoagulant Drugs: Low-Molecular-Weight Heparins
625
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
625
Formation of the Platelet Plug
4.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.8K
Peripheral Artery Disease III: Interprofessional Care
2
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
2
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K

